Standard BioTools Statistics
Total Valuation
LAB has a market cap or net worth of $430.71 million. The enterprise value is $263.20 million.
Important Dates
The last earnings date was Tuesday, November 4, 2025, after market close.
| Earnings Date | Nov 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
LAB has 384.57 million shares outstanding. The number of shares has increased by 35.61% in one year.
| Current Share Class | 384.57M |
| Shares Outstanding | 384.57M |
| Shares Change (YoY) | +35.61% |
| Shares Change (QoQ) | +0.56% |
| Owned by Insiders (%) | 1.42% |
| Owned by Institutions (%) | 46.70% |
| Float | 240.29M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.50 |
| Forward PS | 4.57 |
| PB Ratio | 1.08 |
| P/TBV Ratio | 1.08 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.55 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.38, with a Debt / Equity ratio of 0.07.
| Current Ratio | 4.38 |
| Quick Ratio | 1.93 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -239.68 |
Financial Efficiency
Return on equity (ROE) is -33.26% and return on invested capital (ROIC) is -17.66%.
| Return on Equity (ROE) | -33.26% |
| Return on Assets (ROA) | -14.55% |
| Return on Invested Capital (ROIC) | -17.66% |
| Return on Capital Employed (ROCE) | -32.93% |
| Revenue Per Employee | $207,502 |
| Profits Per Employee | -$156,786 |
| Employee Count | 818 |
| Asset Turnover | 0.28 |
| Inventory Turnover | 2.58 |
Taxes
| Income Tax | -1.64M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -46.92% in the last 52 weeks. The beta is 1.26, so LAB's price volatility has been higher than the market average.
| Beta (5Y) | 1.26 |
| 52-Week Price Change | -46.92% |
| 50-Day Moving Average | 1.30 |
| 200-Day Moving Average | 1.24 |
| Relative Strength Index (RSI) | 37.46 |
| Average Volume (20 Days) | 1,628,245 |
Short Selling Information
The latest short interest is 11.84 million, so 3.08% of the outstanding shares have been sold short.
| Short Interest | 11.84M |
| Short Previous Month | 12.05M |
| Short % of Shares Out | 3.08% |
| Short % of Float | 4.93% |
| Short Ratio (days to cover) | 9.15 |
Income Statement
In the last 12 months, LAB had revenue of $169.74 million and -$128.25 million in losses. Loss per share was -$0.34.
| Revenue | 169.74M |
| Gross Profit | 81.90M |
| Operating Income | -142.13M |
| Pretax Income | -149.49M |
| Net Income | -128.25M |
| EBITDA | -128.49M |
| EBIT | -142.13M |
| Loss Per Share | -$0.34 |
Full Income StatementBalance Sheet
The company has $194.90 million in cash and $27.39 million in debt, giving a net cash position of $167.51 million or $0.44 per share.
| Cash & Cash Equivalents | 194.90M |
| Total Debt | 27.39M |
| Net Cash | 167.51M |
| Net Cash Per Share | $0.44 |
| Equity (Book Value) | 399.66M |
| Book Value Per Share | 1.04 |
| Working Capital | 364.47M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$87.21 million and capital expenditures -$11.21 million, giving a free cash flow of -$98.42 million.
| Operating Cash Flow | -87.21M |
| Capital Expenditures | -11.21M |
| Free Cash Flow | -98.42M |
| FCF Per Share | -$0.26 |
Full Cash Flow StatementMargins
Gross margin is 48.25%, with operating and profit margins of -83.74% and -75.56%.
| Gross Margin | 48.25% |
| Operating Margin | -83.74% |
| Pretax Margin | -88.07% |
| Profit Margin | -75.56% |
| EBITDA Margin | -75.70% |
| EBIT Margin | -83.74% |
| FCF Margin | n/a |
Dividends & Yields
LAB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -35.61% |
| Shareholder Yield | -35.61% |
| Earnings Yield | -29.78% |
| FCF Yield | -22.85% |
Analyst Forecast
The average price target for LAB is $1.35, which is 20.54% higher than the current price. The consensus rating is "Hold".
| Price Target | $1.35 |
| Price Target Difference | 20.54% |
| Analyst Consensus | Hold |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | -15.66% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
LAB has an Altman Z-Score of -0.77 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.77 |
| Piotroski F-Score | 3 |
